The cyclin-dependent kinase 2 (cdk2) is a serine/threonine protein kinase that plays a key role in the cell cycle control system of all eukaryotic organisms. It has been a much studied drug target for potential anticancer therapy. Most cdk2 inhibitors in clinical development target almost exclusively the catalytic ATP-binding pocket of cdk2. However, several five amino-acid peptide inhibitors that are directed towards a noncatalytic binding pocket of cdk2 are reported here. Upon binding to this new pocket located at the cdk2 and cyclin interface, these peptide inhibitors are found to disrupt the cdk2/cyclin E complex partially and diminish its kinase activity in vitro.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4497517 | PMC |
| http://dx.doi.org/10.1002/prot.22136 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reshaping UDP-binding pocket of bacterial sucrose synthase to improve efficiency of UDP-glucose production.
Bioresour Technol
March 2025
Key Laboratory of Industrial Biotechnology (Ministry of Education), School of Biotechnology, Jiangnan University, 1800 Lihu Road, Wuxi, Jiangsu 214122, PR China. Electronic address:
UDP-glucose (UDPG), a nucleoside diphosphate sugar, is an important sugar donor for the biosynthesis of various glycoside compounds. Sucrose synthase (SuSy) can catalyze the synthesis of high-value UDPG from the cost-effective sucrose. By redesigning the substrate-binding pocket of SuSy in Denitrovibrio acetiphilus DSM 12809, a variant with 8.
View Article and Find Full Text PDFExpanding the utilization of binding pockets proves to be effective for noncovalent small molecule inhibitors against SARS-CoV-2 M.
Eur J Med Chem
March 2025
State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, 511436, China; Guangzhou National Laboratory, Guangzhou, 510005, China; Innovative Center for Pathogen Research, Guangzhou National Laboratory, Guangzhou, 510005, China; The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 511436, China; University of South China, Hengyang, 421001, China. Electronic address:
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths and continues to pose serious threats to global public health. The main protease (M) of SARS-CoV-2 is crucial for viral replication and its conservation, making it an attractive drug target. Here, we employed a structure-based drug design strategy to develop and optimize novel inhibitors targeting SARS-CoV-2 M.
View Article and Find Full Text PDFAminoisothiazolamides, a new class of potent inhibitors of lysyl-tRNA synthetase.
Pest Manag Sci
March 2025
Research & Development, Weed Control, Division Crop Science, Bayer AG, Industriepark Höchst, Frankfurt am Main, Germany.
Background: Owing to the economic relevance of resistance evolution against herbicides, new chemical entities addressing unprecedented molecular targets are urgently needed to develop future sustainable weed control solutions. As part of our discovery research, the new class of aminoisothiazolamides was investigated.
Results: Aminoisothiazolamide 3-amino-4-chloro-N-(cyclohexylmethyl)isothiazole-5-carboxamide 1a and several of its derivatives displayed potent herbicidal and fungicidal in vivo activity in initial glasshouse tests.
Asciminib: the tyrosine kinase inhibitor with a unique mechanism of action.
Expert Opin Pharmacother
March 2025
Georgia Cancer Center, Cecil F. Whitaker Jr. GRA Eminent Scholar Chair in Cancer, Augusta, GA, USA.
Introduction: Management of chronic phase chronic myeloid leukemia (CML-CP) was revolutionized with the development of tyrosine kinase inhibitors (TKIs). Imatinib (first generation), dasatinib, nilotinib and bosutinib (second generation) and ponatinib (third generation) are the five approved TKIs that inhibit BCR::ABL1 by binding to the ATP binding site of ABL1. About half of the resistance to TKIs develops through acquisition of mutations in the ATP binding site, including T315I.
View Article and Find Full Text PDFUSP7 V517F mutation as a mechanism of inhibitor resistance.
Nat Commun
March 2025
State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, China.
Anticipating and addressing resistance is essential for maximizing the potential of an oncology target and effectively addressing clinical needs. In this study, we aimed to proactively outline the resistance mechanisms of USP7 inhibitors. We discovered a key treatment-emergent heterozygous mutation (V517F) in USP7 in the binding pocket of compounds as the primary cause of resistance to the USP7 inhibitor USP7-797.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!